共 597 条
[1]
Brawley OW(2012)Trends in prostate cancer in the United States J Natl Cancer Inst Monogr 2012 152-156
[2]
Scher HI(2015)Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model PLoS One 10 e0139440-244
[3]
Solo K(2005)Androgen deprivation therapy for prostate cancer JAMA 294 238-1418
[4]
Valant J(2016)Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 J Clin Oncol 34 1402-245
[5]
Todd MB(2008)Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 242-1512
[6]
Mehra M(2004)Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502-1520
[7]
Sharifi N(2004)Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 1513-2005
[8]
Gulley JL(2011)Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 1995-1197
[9]
Dahut WL(2012)Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 1187-160
[10]
Scher HI(2015)Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 16 152-433